Dianthus Therapeutics is focused on developing innovative monoclonal antibodies that target the complement system, specifically through their lead product, DNTH103. This investigational antibody is engineered to selectively inhibit the active form of the C1s protein, which plays a critical role in the classical complement pathway associated with various autoimmune diseases. DNTH103 is designed with extended half-life capabilities, allowing for less frequent subcutaneous self-administration, potentially as infrequently as once every two weeks. This selectivity not only aims to enhance the therapeutic efficacy of the treatment but also seeks to minimize the risk of infections by preserving the immune activity of other complement pathways.

The company is advancing DNTH103 through multiple clinical trials targeting severe autoimmune conditions, including generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN), and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The ongoing Phase 2 trials for gMG and MMN, along with the anticipated Phase 3 trial for CIDP, underscore the potential of DNTH103 as a best-in-class therapy. With promising preclinical and early clinical data supporting its safety and efficacy, Dianthus Therapeutics aims to address significant unmet medical needs in the treatment of these debilitating conditions, thereby improving the quality of life for affected patients.

United States

Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency.  Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.

Immune System Diseases

Dianthus Therapeutics

Cancer

Multiple myeloma

<p class="font_7">MGTA-145 is being developed in combination with plerixafor to harness complementary chemokine mechanisms to mobilize hematopoietic stem cells for collection and transplantation. This new combination has the potential to be the preferred mobilization regimen for rapid and reliable mobilization and collection of hematopoietic stem cells to improve outcomes in autologous and allogeneic stem cell transplantation, which can rebuild a healthy immune system for patients with blood cancers, genetic diseases and autoimmune disorders.</p>
<p class="font_7">MGTA-145 has the potential to replace the current standard of care for patients and allogeneic donors who currently rely on the use of granulocyte-colony stimulating factor (G-CSF) alone or in combination with plerixafor, which can take up to five days or longer to mobilize sufficient numbers of stem cells, often resulting in significant bone pain and other side effects.</p>

Dianthus Therapeutics

Company Details